NCT02720068View on ClinicalTrials.gov

Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001)

PHASE1CompletedINTERVENTIONAL

Enrollment

481

Participants

Timeline

Start Date

May 2, 2016

Primary Completion Date

March 15, 2024

Study Completion Date

March 15, 2024

Conditions

Neoplasms

Interventions

BIOLOGICAL

Favezelimab

IV infusion

BIOLOGICAL

Pembrolizumab

IV infusion

DRUG

Oxaliplatin

IV infusion

DRUG

Irinotecan

IV infusion

DRUG

Leucovorin (Calcium Folinate)

IV infusion

DRUG

Fluorouracil [5-FU]

IV infusion

BIOLOGICAL

Favezelimab/Pembrolizumab

IV infusion

DRUG

Lenvatinib

Oral

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02720068 - Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001) | Biotech Hunter | Biotech Hunter